The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback